Home › Cancer (all types) › NCT02253251
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
RecruitingObservational studyHealthy volunteers welcome
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Personal or family history of cancer * Personal history of endometriosis, or autoimmunity Exclusion Criteria: * Younger than 18 * Non-english speaking and unable to understand and sign the consent
About the study
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
What is being tested
- KRAS-variant and microRNA binding site mutation testing (genetic)
Sponsor: MiraKind · Participants: 15,000 · Started: 2014-09
Contact the study team
- Joanne Weidhaas, MDPhD · Phone: 203-671-1308
- Joanne Weidhaas · Phone: 424-387-8100
Official record on ClinicalTrials.gov — NCT02253251
Locations in the U.S.
| California | MiraKind, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.